Compare JRSH & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | ELUT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 48.3M |
| IPO Year | 2017 | 2020 |
| Metric | JRSH | ELUT |
|---|---|---|
| Price | $4.59 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 892.5K | 88.5K |
| Earning Date | 02-09-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | ★ 485.71 | 146.77 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $166,263,870.00 | $12,293,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $10.06 | $10.83 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $2.85 | $0.50 |
| 52 Week High | $5.47 | $2.60 |
| Indicator | JRSH | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 76.80 | 45.27 |
| Support Level | $3.09 | $0.87 |
| Resistance Level | $5.47 | $0.99 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 59.17 | 29.41 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.